ClinicalTrials.gg
CompletedNCT05217927Updated Dec 16, 2025Results posted

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

A Phase 4 interventional study of Rimegepant 75mg daily dosing and Rimegepant 75mg every other day dosing in Migraine, sponsored by Pfizer. Completed at 107 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,415
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
8th of 32
1,415 · median 618
Started
2022
with 7 others
Phase 4
9 of 32
4 open now
Registered
13th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 8th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 4, and was the 13th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
  • Episodic Migraine
  • Adult Migraine
  • Calcitonin Gene-related Peptide
  • Migraine Prevention
  • Migraine Prophylaxis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1) Target Population: Subject has at least 1 year history of episodic migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:

  1. Age of onset of migraines prior to 50 years of age
  2. Migraine attacks, on average, lasting 4-72 hours if untreated
  3. Per subject report, 4-14 migraine attacks per month within the last 3 months prior to the Screening Visit (month is defined as 4 weeks for the purpose of this protocol

Exclusion criteria

Exclusion Criteria:

  1. Sex and Reproductive Status:

    1. who are unwilling or unable to use an acceptable method or abstinence to avoid pregnancy for the entire study and for 60 days after the last dose of study drug
    2. Women who are pregnant or breastfeeding
    3. Women with a positive pregnancy test at screening or prior to study drug administration
  2. Prohibited Medications:

    1. Use of prophylactic migraine medication within 30 days prior to the Screening Visit.
    2. History of use of analgesics (e.g., non-steroidal anti-inflammatory drugs [NSAIDs] or acetaminophen) on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit.
    3. Use of medication accepted for treatment of acute migraine for a nonmigraine indication on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit.
    4. Subjects who previously discontinued biologic migraine medication must have done so at least 6 months (24 weeks) prior to the Screening Visit.
    5. Subjects taking a prohibited medication as defined per protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,415 participants (actual)

Study arms

  • Experimental
    Rimegepant 75mg Orally Disitegrating Tablet (ODT)daily dosing

    Double-blind Treatment Phase: Rimegepant 75 mg ODT dosed daily Open-Label Extension Phase: Rimegepant 75 mg ODT dosed daily

    Drug: Rimegepant 75mg daily dosing

  • Experimental
    Rimegepant 75mg Orally Disintegrating Tablet (ODT)every other day dosing

    Double-blind Treatment Phase: Rimegepant 75 mg ODT every other day dosing alternating with matching placebo

    Drug: Rimegepant 75mg every other day dosing

  • Placebo comparator
    Placebo comparator dosing

    Double-blind Treatment Phase: matching placebo dosed daily

    Drug: Placebo comparator dosing

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

    A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]). Mean change in number of migraine days per month in DBT phase as compared to OP phase was calculated and reported in this outcome measure.

    Time frame: Observation phase (from 31 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])

Secondary outcomes

  1. Percentage of Participants With Greater Than Equal to (>=) 50 Percent (%) Reduction From OP in Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    Percentage of participants with \>= 50% reduction from OP, in number of migraine days (moderate or severe) in the overall DBT phase is reported in this outcome measure. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).

    Time frame: DBT phase (through Month 3 [Week 1 to 12])

  2. Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase

    A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month) / (total number of e-diary efficacy data in the month). Mean change in number of migraine days per month in the last 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.

    Time frame: Observation phase (from 31 days before randomization), Week 9 to Week 12 of the DBT phase

  3. Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase

    A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month / (total number of e-diary efficacy data in the month. Mean change in number of migraine days per month in the first 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.

    Time frame: Observation phase (from 31 days before randomization), Week 1 to Week 4 of the DBT phase

  4. Mean Number of Acute Migraine-Specific Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    An acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (i.e., triptan or ergotamine). The number of acute migraine-specific medication days per month were prorated to 28 days and derived for on-DBT efficacy analysis period as follows: 28\*(total number of acute migraine-specific medication days through Month 3/ (total number of e-Diary efficacy data days through Month 3).

    Time frame: DBT phase (through Month 3 [Week 1 to 12])

  5. Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase

    MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Participants were required to respond to items using a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.

    Time frame: Baseline (Day 1), Week 12 of the DBT phase

  6. Number of Participants With Mild, Moderate and Severe Adverse Events (AEs) in DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and serious adverse events (SAEs).

    Time frame: DBT: From Week 1 to Week 20

  7. Number of Participants With Mild, Moderate and Severe AEs OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and SAEs.

    Time frame: OLE: From Week 12 to Week 32

  8. Number of Participants With Serious Adverse Events (SAEs) in DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.

    Time frame: DBT: From Week 1 to Week 20

  9. Number of Participants With SAEs in OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.

    Time frame: OLE: From Week 12 to Week 32

  10. Number of Participants With AEs Leading to Study Drug Discontinuation in DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.

    Time frame: DBT: From Week 1 to Week 12

  11. Number of Participants With AEs Leading to Study Drug Discontinuation in OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.

    Time frame: OLE: From Week 12 to Week 24

  12. Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase

    The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0 and using division of AIDS (DAIDS) toxicity grading scale version 2.1 (glucose, low density lipoprotein \[LDL\] cholesterol, uric acid and urinalysis) and for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase ,aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity were graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.

    Time frame: DBT: From Week 1 to Week 20

  13. Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase

    The laboratory parameters were graded according to the NCI CTCAE version 5.0 and using DAIDS toxicity grading scale version 2.1 (glucose, LDL cholesterol, uric acid and urinalysis). And for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity was graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.

    Time frame: OLE: From Week 12 to Week 32

  14. Number of Participants With Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Elevations > 3* Upper Limit of Normal (ULN) Concurrent With (Total Bilirubin) TBL >2*ULN in DBT Phase

    Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.

    Time frame: DBT: From Week 1 to Week 20

  15. Number of Participants With AST or ALT Elevations > 3* ULN Concurrent With TBL >2*ULN in OLE Phase

    Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.

    Time frame: OLE: From Week 12 to Week 32

  16. Number of Participants With Hepatic-Related AEs in the DBT Phase

    \\An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, liver function test increased, bilirubin conjugated increased, blood bilirubin increased, transaminases increased and hyperbilirubinemia. Number of participants with any hepatic-related AEs in the DBT phase were reported in this outcome measure.

    Time frame: DBT: From Week 1 to Week 20

  17. Number of Participants With Hepatic-Related AEs in the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, bilirubin conjugated, hepatic enzyme increased, blood bilirubin unconjugated increased, blood bilirubin and transaminases increased and hepatic function abnormal. Number of participants with any hepatic-related AEs in the OLE phase were reported in this outcome measure.

    Time frame: OLE: From Week 12 to Week 32

  18. Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test and blood bilirubin increased. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.

    Time frame: DBT: From Week 1 to Week 12

  19. Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: aspartate aminotransferase increased and liver function test abnormal. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.

    Time frame: OLE: From Week 12 to Week 24

07

Results

Posted Dec 16, 2025

Participant flow

DBT Phase
Participant flow — DBT Phase
MilestoneDouble Blind (DB) Rimegepant/ Placebo/ Open Label (OL) RimegepantDB Rimegepant/OL RimegepantDB Placebo/OL Rimegepant
Started234232233
Treated232229231
Completed204209208
Not completed302325
Withdrew: Adverse event725
Withdrew: Lack of efficacy100
Withdrew: Lost to follow-up020
Withdrew: Non-compliance100
Withdrew: Pregnancy001
Withdrew: Protocol violation021
Withdrew: Protocol-specified withdrawal criterion met465
Withdrew: Withdrawal of consent857
Withdrew: Other734
Withdrew: Randomized, not treated232
OLE Phase
Participant flow — OLE Phase
MilestoneDouble Blind (DB) Rimegepant/ Placebo/ Open Label (OL) RimegepantDB Rimegepant/OL RimegepantDB Placebo/OL Rimegepant
Started182196195
Completed170187183
Not completed12912
Withdrew: Adverse event411
Withdrew: Extension phase eligibility failure100
Withdrew: Lost to follow-up121
Withdrew: Non-compliance001
Withdrew: Other354
Withdrew: Withdrawal of consent315

Outcome measures

PrimaryMean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]). Mean change in number of migraine days per month in DBT phase as compared to OP phase was calculated and reported in this outcome measure.

Time frame:
Observation phase (from 31 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])
Reported as:
Least squares mean · Days per month
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
Days per monthDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)-2.9 (-3.31 to -2.42)-4.0 (-4.44 to -3.60)-2.2 (-2.65 to -1.85)
Statistical analysis
  • DB Rimegepant/ Placebo vs DB Placebo · Mixed Models Analysis · p = =0.0220 · Least square mean (lsm) difference: -0.6 · 97.5% CI -1.22 to -0.01
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 · Lsm difference: -1.8 · 97.5% CI -2.35 to -1.19
SecondaryPercentage of Participants With Greater Than Equal to (>=) 50 Percent (%) Reduction From OP in Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

Percentage of participants with \>= 50% reduction from OP, in number of migraine days (moderate or severe) in the overall DBT phase is reported in this outcome measure. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).

Time frame:
DBT phase (through Month 3 [Week 1 to 12])
Reported as:
Number · Percentage of participants
Percentage of Participants With Greater Than Equal to (>=) 50 Percent (%) Reduction From OP in Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Percentage of participantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Percentage of Participants With Greater Than Equal to (>=) 50 Percent (%) Reduction From OP in Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)40.5 (33.5 to 47.9)58.1 (50.7 to 65.3)33.3 (26.4 to 40.2)
Statistical analysis
  • DB Rimegepant/ Placebo vs DB Placebo · Mantel Haenszel · p = =0.0966 · Difference in percentage: 7.4 · 97.5% CI -2.6 to 17.4
  • DB Rimegepant vs DB Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 24.7 · 97.5% CI 14.6 to 34.8
SecondaryMean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase

A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month) / (total number of e-diary efficacy data in the month). Mean change in number of migraine days per month in the last 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.

Time frame:
Observation phase (from 31 days before randomization), Week 9 to Week 12 of the DBT phase
Reported as:
Least squares mean · Days per month
Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase
Days per monthDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase-3.0 (-3.59 to -2.49)-4.2 (-4.75 to -3.75)-2.8 (-3.33 to -2.33)
Statistical analysis
  • DB Rimegepant/ Placebo vs DB Placebo · Mixed Models Analysis · p = =0.5314 · Ls mean difference: -0.2 · 97.5% CI -0.95 to 0.54
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.4 · 97.5% CI -2.12 to -0.71
SecondaryMean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase

A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month / (total number of e-diary efficacy data in the month. Mean change in number of migraine days per month in the first 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.

Time frame:
Observation phase (from 31 days before randomization), Week 1 to Week 4 of the DBT phase
Reported as:
Least squares mean · Days per month
Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase
Days per monthDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase-2.7 (-3.17 to -2.16)-3.6 (-4.10 to -3.16)-1.5 (-1.97 to -1.05)
Statistical analysis
  • DB Rimegepant/ Placebo vs DB Placebo · Mixed Models Analysis · p = =0.0002 · Ls mean difference: -1.2 · 97.5% CI -1.84 to -0.47
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -2.1 · 97.5% CI -2.78 to -1.46
SecondaryMean Number of Acute Migraine-Specific Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

An acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (i.e., triptan or ergotamine). The number of acute migraine-specific medication days per month were prorated to 28 days and derived for on-DBT efficacy analysis period as follows: 28\*(total number of acute migraine-specific medication days through Month 3/ (total number of e-Diary efficacy data days through Month 3).

Time frame:
DBT phase (through Month 3 [Week 1 to 12])
Reported as:
Least squares mean · Days per month
Mean Number of Acute Migraine-Specific Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Days per monthDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Mean Number of Acute Migraine-Specific Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)2.3 (1.87 to 2.82)1.5 (1.13 to 1.88)2.8 (2.28 to 3.35)
Statistical analysis
  • DB Rimegepant/ Placebo vs DB Placebo · Mixed Models Analysis · p = =0.1440 · Ls mean difference: -0.5 · 97.5% CI -1.20 to 0.25
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.3 · 97.5% CI -1.97 to -0.65
SecondaryMean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase

MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Participants were required to respond to items using a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.

Time frame:
Baseline (Day 1), Week 12 of the DBT phase
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase
Units on a scaleDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase21.3 (18.37 to 24.33)29.1 (25.79 to 32.31)18.9 (15.91 to 21.97)
Statistical analysis
  • DB Rimegepant/ Placebo vs DB Placebo · Regression, Linear · p = =0.2029 · Ls mean difference: 2.4 · 97.5% CI -1.84 to 6.66
  • DB Rimegepant vs DB Placebo · Regression, Linear · p = <0.0001 · Ls mean difference: 10.1 · 97.5% CI 5.71 to 14.52
SecondaryNumber of Participants With Mild, Moderate and Severe Adverse Events (AEs) in DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and serious adverse events (SAEs).

Time frame:
DBT: From Week 1 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Mild, Moderate and Severe Adverse Events (AEs) in DBT Phase
ParticipantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Mild738691
Moderate422243
Severe432
SecondaryNumber of Participants With Mild, Moderate and Severe AEs OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and SAEs.

Time frame:
OLE: From Week 12 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Mild, Moderate and Severe AEs OLE Phase
ParticipantsDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Mild655765
Moderate302225
Severe221
SecondaryNumber of Participants With Serious Adverse Events (SAEs) in DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.

Time frame:
DBT: From Week 1 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) in DBT Phase
ParticipantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Number of Participants With Serious Adverse Events (SAEs) in DBT Phase321
SecondaryNumber of Participants With SAEs in OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.

Time frame:
OLE: From Week 12 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With SAEs in OLE Phase
ParticipantsDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Number of Participants With SAEs in OLE Phase222
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation in DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.

Time frame:
DBT: From Week 1 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation in DBT Phase
ParticipantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Number of Participants With AEs Leading to Study Drug Discontinuation in DBT Phase614
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation in OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.

Time frame:
OLE: From Week 12 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation in OLE Phase
ParticipantsDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Number of Participants With AEs Leading to Study Drug Discontinuation in OLE Phase411
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase

The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0 and using division of AIDS (DAIDS) toxicity grading scale version 2.1 (glucose, low density lipoprotein \[LDL\] cholesterol, uric acid and urinalysis) and for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase ,aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity were graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.

Time frame:
DBT: From Week 1 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase
ParticipantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Lymphocytes, low001
Alanine Aminotransferase011
Aspartate Aminotransferase001
Creatine Kinase214
Glucose, low010
LDL Cholesterol649
LDL Cholesterol, fasting433
LDL Cholesterol, not fasting216
Sodium, high001
Triglycerides010
Triglycerides, fasting010
Urinalysis Glucose010
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase

The laboratory parameters were graded according to the NCI CTCAE version 5.0 and using DAIDS toxicity grading scale version 2.1 (glucose, LDL cholesterol, uric acid and urinalysis). And for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity was graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.

Time frame:
OLE: From Week 12 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase
ParticipantsDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Alanine Aminotransferase111
Aspartate Aminotransferase010
Creatine Kinase305
LDL Cholesterol784
LDL Cholesterol, fasting440
LDL Cholesterol, not fasting344
Potassium, low010
Potassium, high101
Triglycerides010
Triglycerides, not fasting010
Urinalysis Glucose110
SecondaryNumber of Participants With Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Elevations > 3* Upper Limit of Normal (ULN) Concurrent With (Total Bilirubin) TBL >2*ULN in DBT Phase

Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.

Time frame:
DBT: From Week 1 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Elevations > 3* Upper Limit of Normal (ULN) Concurrent With (Total Bilirubin) TBL >2*ULN in DBT Phase
ParticipantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Number of Participants With Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Elevations > 3* Upper Limit of Normal (ULN) Concurrent With (Total Bilirubin) TBL >2*ULN in DBT Phase000
SecondaryNumber of Participants With AST or ALT Elevations > 3* ULN Concurrent With TBL >2*ULN in OLE Phase

Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.

Time frame:
OLE: From Week 12 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With AST or ALT Elevations > 3* ULN Concurrent With TBL >2*ULN in OLE Phase
ParticipantsDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Number of Participants With AST or ALT Elevations > 3* ULN Concurrent With TBL >2*ULN in OLE Phase000
SecondaryNumber of Participants With Hepatic-Related AEs in the DBT Phase

\\An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, liver function test increased, bilirubin conjugated increased, blood bilirubin increased, transaminases increased and hyperbilirubinemia. Number of participants with any hepatic-related AEs in the DBT phase were reported in this outcome measure.

Time frame:
DBT: From Week 1 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-Related AEs in the DBT Phase
ParticipantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Number of Participants With Hepatic-Related AEs in the DBT Phase788
SecondaryNumber of Participants With Hepatic-Related AEs in the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, bilirubin conjugated, hepatic enzyme increased, blood bilirubin unconjugated increased, blood bilirubin and transaminases increased and hepatic function abnormal. Number of participants with any hepatic-related AEs in the OLE phase were reported in this outcome measure.

Time frame:
OLE: From Week 12 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-Related AEs in the OLE Phase
ParticipantsDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Number of Participants With Hepatic-Related AEs in the OLE Phase1146
SecondaryNumber of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test and blood bilirubin increased. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.

Time frame:
DBT: From Week 1 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the DBT Phase
ParticipantsDB Rimegepant/ PlaceboDB RimegepantDB Placebo
Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the DBT Phase412
SecondaryNumber of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: aspartate aminotransferase increased and liver function test abnormal. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.

Time frame:
OLE: From Week 12 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the OLE Phase
ParticipantsDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the OLE Phase111

Adverse events

Collected over Baseline up to 8 weeks after last dose of study drug (DBT phase: Week 1 to Week 20; OLE phase Week 12 to Week 32). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Rimegepant/ Placebo0/232 (0%)3/232 (1.3%)13/232 (5.6%)
DB Rimegepant0/229 (0%)2/229 (0.9%)13/229 (5.7%)
DB Placebo0/231 (0%)1/231 (0.4%)13/231 (5.6%)
DB RMG EOD/DB PBO EOD/ OL RMG QD0/182 (0%)2/182 (1.1%)17/182 (9.3%)
DB RMG QD/ OL RMG QD0/196 (0%)2/196 (1%)19/196 (9.7%)
DB PBO QD/ OL RMG QD0/195 (0%)2/195 (1%)13/195 (6.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventDB Rimegepant/ PlaceboDB RimegepantDB PlaceboDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
Back painMusculoskeletal and connective tissue disorders0/2320/2290/2311/1820/1960/195
Status migrainosusNervous system disorders1/2320/2290/2311/1820/1960/195
AppendicitisInfections and infestations0/2320/2290/2310/1820/1961/195
Post procedural haemorrhageInjury, poisoning and procedural complications0/2320/2290/2310/1820/1961/195
Liver function test abnormalInvestigations0/2320/2290/2310/1821/1960/195
CostochondritisMusculoskeletal and connective tissue disorders0/2320/2290/2310/1821/1960/195
Infected cystInfections and infestations0/2321/2290/2310/1820/1960/195
Urinary tract infectionInfections and infestations0/2321/2290/2310/1820/1960/195
PneumoniaInfections and infestations0/2320/2291/2310/1820/1960/195
Crohn's diseaseGastrointestinal disorders1/2320/2290/2310/1820/1960/195
Most frequent other events
Most frequent other events
EventDB Rimegepant/ PlaceboDB RimegepantDB PlaceboDB RMG EOD/DB PBO EOD/ OL RMG QDDB RMG QD/ OL RMG QDDB PBO QD/ OL RMG QD
NasopharyngitisInfections and infestations13/23213/22913/23113/1825/1967/195
COVID-19Infections and infestations0/2320/2290/2314/18214/1966/195

Baseline characteristics

Double-blind treatment safety population included participants in the enrolled analysis set who took greater than equal to (\>=) 1 dose of double-blind study drug (rimegepant or placebo).

Age, Continuous
Age, Continuous(Years)DB Rimegepant/ Placebo/ OL RimegepantDB Rimegepant/OL RimegepantDB Placebo/OL RimegepantTotal
Mean42.0 ± 11.9643.9 ± 12.0542.9 ± 12.3543 ± 12.13
Sex: Female, Male
Sex: Female, Male(Participants)DB Rimegepant/ Placebo/ OL RimegepantDB Rimegepant/OL RimegepantDB Placebo/OL RimegepantTotal
Female201192207600
Male31372492
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB Rimegepant/ Placebo/ OL RimegepantDB Rimegepant/OL RimegepantDB Placebo/OL RimegepantTotal
Hispanic or Latino23202568
Not Hispanic or Latino475051148
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB Rimegepant/ Placebo/ OL RimegepantDB Rimegepant/OL RimegepantDB Placebo/OL RimegepantTotal
American Indian or Alaska Native1001
Asian51612
Native Hawaiian or Other Pacific Islander1012
Black or African American612624
White565663175
More than one race0101
Unknown or Not Reported1001
08

Study locations

107 sites
  • AMR Clinical
    Tempe, Arizona 85281, United States
  • Axiom Research, Llc
    Colton, California 92324, United States
  • Clinical Research Institute
    Los Angeles, California 90048, United States
  • Wr-Pri, Llc
    Newport Beach, California 92660, United States
  • California Neuroscience Research Medical Group, inc.
    Sherman Oaks, California 91403, United States
  • Neurology Offices of South Florida, PLLC
    Boca Raton, Florida 33428, United States
  • AppleMed Research Group, LLC
    Miami, Florida 33126, United States
  • Clinical Investigation Specialists, Inc.
    Gurnee, Illinois 60031, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Collective Medical Research
    Overland Park, Kansas 66210, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65807, United States
  • Alliance for Multispecialty Research, LLC
    Las Vegas, Nevada 89119, United States
  • Dent Neurosciences Research Center, Inc.
    Amherst, New York 14226, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Upstate Clinical Research Associates, LLC
    Williamsville, New York 14221, United States
  • Wellnow Urgent Care and Research
    Columbus, Ohio 43228, United States
  • Hometown Urgent Care and Research
    Huber Heights, Ohio 45424, United States
  • Velocity Clinical Research, Medford
    Medford, Oregon 97504, United States
  • Preferred Primary Care Physicians, Inc.
    Pittsburgh, Pennsylvania 15236, United States
  • Velocity Clinical Research - Providence
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research - Columbia
    Columbia, South Carolina 29204, United States
  • Velocity Clinical Research, Gaffney
    Gaffney, South Carolina 29340, United States
  • Tribe Clinical Research LLC
    Greenville, South Carolina 29607, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • APD Clinical Research
    Magnolia, Texas 77355, United States
  • Wasatch Clinical Research , LLC(Administrative Location)
    Salt Lake City, Utah 84107, United States
  • Seattle Clinical Research Center
    Seattle, Washington 98105, United States
  • Medizinische Universitat Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • Christian-Doppler-Klinik
    Salzburg, 5020, Austria
  • Calgary Headache & Assessment Management Program (CHAMP)
    Calgary, Alberta T3M 1M4, Canada
  • OCT Research ULC
    Kelowna, British Columbia V1Y 1Z9, Canada
  • James K. Lai MD Inc.
    Vancouver, British Columbia V5Z 1K3, Canada
  • Centricity Research
    Halifax, Nova Scotia B3S 1N2, Canada
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T 0G1, Canada
  • Manna Research Inc. (Burlington North)
    Burlington, Ontario L7M 4Y1, Canada
  • Milestone Research Inc.
    London, Ontario N5W 6A2, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, Ontario N7T 4X3, Canada
  • Mirtorabi Medicine Professional Corporation
    Stouffville, Ontario L4A 1H2, Canada
  • Toronto Memory Program
    Toronto, Ontario M3B 2S7, Canada
  • Manna Research (Toronto)
    Toronto, Ontario M9W 4L6, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Hopital Gabriel Montpied
    Clermont-Ferrand, 63003, France
  • Hopital de La Timone
    Marseille, 13385, France
  • Klinische Forschung Karlsruhe GmbH
    Karlsruhe, Baden-Wurttemberg 76137, Germany
  • Vitos Orthopaedische Klinik Kassel
    Kassel, Hesse 34131, Germany
  • Siteworks - Zentrum fur klinische Studien Hannover
    Hanover, Lower Saxony 30449, Germany
  • Arztepartnerschaft Dr. med. J. Springub/ W. Schwarz -Studienzentrum Nord-West
    Westerstede, Lower Saxony 26655, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, Saxony 01069, Germany
  • Universitatsklinikum Jena
    Jena, Thuringia 07747, Germany
  • Studienzentrum Dr. A Schwittay
    Böhlen, 04564, Germany
  • Datamed GmbH
    Cologne, 50935, Germany
  • Kopfschmerzzentrum Frankfurt
    Frankfurt, 65929, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, 20253, Germany
  • Neurologisch-verhaltensmedizinische Schmerzklinik Kiel
    Kiel, 24194, Germany
  • Ospedale Sant Andrea - Facolta Medicina Psicologia - Universita degli Studi di Roma Sapienza
    Rome, Lazio 00189, Italy
  • Fondazione Mondino - Istituto Neurologico Nazionale IRCCS
    Pavia, Padua 27100, Italy
  • Azienda Ospedaliero Universitaria di Careggi - Cliniche Mediche
    Florence, Tuscany 50134, Italy
  • IRCCS Istituto delle Scienze Neurologiche Bologna, Unità Operativa di Neurologia - Ospedale Bellaria
    Bologna, 40139, Italy
  • ASST Spedali Civili di Brescia, U.O. Neurologia
    Brescia, 25123, Italy
  • Neurorehabilitation Unit-ICOT Istituto Marco Pasquali
    Latina, 04100, Italy
  • Istituto Neurologico "Carlo Besta" Fondazione IRCCS
    Milan, 20133, Italy
  • IRCCS San Raffaele Roma
    Rome, 00197, Italy
  • Solumed Centrum Medyczne
    Poznan, Greater Poland Voivodeship 60-529, Poland
  • Centrum Medyczne Pratia Bydgoszcz
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Pratia MCM Krakow
    Krakow, Lesser Poland Voivodeship 30-510, Poland
  • Krakowska Akademia Neurologii Sp. Z o.o.
    Krakow, Lesser Poland Voivodeship 31-505, Poland
  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
    Wroclaw, Lower Silesian Voivodeship 52-210, Poland
  • Indywidualna Praktyka Lekarska Dr Hab. Med. Anna Szczepanska-Szerej
    Lublin, Lublin Voivodeship 20-582, Poland
  • Next Stage Sp. Z o.o.
    Warsaw, Masovian Voivodeship 02-121, Poland
  • Wojskowy Instytut Medyczny
    Warsaw, Masovian Voivodeship 04-141, Poland
  • Centrum Medyczne Pratia Czestochowa
    Częstochowa, Silesian Voivodeship 42-200, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, Silesian Voivodeship 40-081, Poland
  • NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS
    Katowice, Silesian Voivodeship 40-123, Poland
  • Neurologia Slaska Centrum Medyczne
    Katowice, Silesian Voivodeship 40-689, Poland
  • NZOZ Neuromed M. i M. Nastaj Sp. P.
    Lublin, 20-064, Poland
  • MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
  • Neurology Service: Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Clinico Universitario de Valladolid • HCUV
    Valladolid, Castille and León 47003, Spain
  • Hospital Alvaro Cunqueiro
    Vigo, Pontevedra 36312, Spain
  • Instituto de Investigaciones del Sueno
    Madrid, 28036, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Virgen del Rocio Hospital
    Seville, 41013, Spain
  • Hospital Universitario y Politecnico La Fe
    Valencia, 46026, Spain
  • Pharmasite
    Malmö, Skåne County 21152, Sweden
  • CTC Clinical Trial Consultants AB
    Stockholm, Stockholms LÄN [se-01] 171 64, Sweden
  • Ladulaas Clinical Trials
    Borås, SE 506 30, Sweden
  • ProbarE i Lund
    Lund, 222 22, Sweden
  • ProbarE i Stockholm AB
    Stockholm, 113 29, Sweden
  • Studieenheten Akademiskt Specialistcentrum SLSO
    Stockholm, 11361, Sweden
  • Royal Primary Care Ashgate, Chesterfield Royal Hospital, NHS Foundation Trust
    Chesterfield, Derbyshire S40 4AA, United Kingdom
  • Panthera Biopartners
    Rochdale, Great Manchester O11 4AU, United Kingdom
  • Re:Cognition Health - Winchester
    Winchester, Hampshire SO21 1HU, United Kingdom
  • Panthera Bio Partners
    Preston, Lancashire PR2 9QB, United Kingdom
  • Re:Cognition Health - London
    London, Marylebone W1G 9JF, United Kingdom
  • Re:Cognition Health-Private Practice
    London, Marylebone W1G9RU, United Kingdom
  • Lakeside Healthcare Research
    Corby, Northamptonshire NN17 2UR, United Kingdom

Showing the first 100 of 107 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Oct 2024, 31 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 31 months is above that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 1, 2022
StartActual
Mar 4, 2022
Primary completionActual
Oct 22, 2024
CompletionActual
Dec 11, 2024
Results first posted
Dec 16, 2025
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05217927
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 1, 2022
Start date
Mar 4, 2022
Primary completion
Oct 22, 2024
Completion
Dec 11, 2024
Results posted
Dec 16, 2025
Last update
Dec 16, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion